SCHEMBL3783598

SCHEMBL3783598

Cc1nc2c(Cl)ccc(O)c2c(C)c1Oc1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.36
ENPP3 O14638 1/20 0.36
ALPL P05186 1/20 0.36
ENPP1 P22413 1/20 0.36
XIAP P98170 1/20 0.36
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
EGLN1 Q9GZT9 1/20 0.34
ALDH1A1 P00352 2/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
GPR55 Q9Y2T6 1/20 0.33
ALOX5 P09917 1/20 0.33
POLB P06746 1/20 0.33
NPBWR1 P48145 2/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
SLC2A1 P11166 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27826429 0.80 KDM4E (0.38) TSHRENPP3ALPLENPP1XIAP
SCHEMBL3784536 0.79 EGLN1 (0.39) ENPP3ALPLENPP1XIAPKDM4E
SCHEMBL3778902 0.78 PPARD (0.46) TSHRKDM4EEGLN1MAPT
SCHEMBL3777897 0.76 PTGS2 (0.43) KDM4ELMNAALDH1A1MAPTSMN1; SMN2
SCHEMBL3778746 0.74 TP53 (0.39) LMNAALDH1A1MAPT
SCHEMBL3775557 0.73 KMT2A (0.40) ENPP1KDM4EEGLN1ALDH1A1MAPT
SCHEMBL28853442 0.62 KDM4E (0.39) TSHRKDM4ELMNAEGLN1ALDH1A1
SCHEMBL30661041 0.62 KDM4E (0.39) TSHRKDM4ELMNAEGLN1ALDH1A1
SCHEMBL11296576 0.61 TSHR (0.43) TSHRKDM4EALDH1A1MAPTPOLB
SCHEMBL11298129 0.61 TTR (0.47) TSHRLMNAALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
CN-101316591-B Quinoline compound and pharmaceutical application thereof ARGENTA ORAL THERAPEUTICS LTD. (GB) 2012-02-01 CN disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
CN-101316591-A Quinolines and their therapeutic use ARGENTA DISCOVERY LTD (GB) 2008-12-03 CN disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 TSHR 73/4885ENPP3 2009/4885ALPL 4652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.